The company reported revenue of $2.2 billion for the third quarter of 2023, an increase of 7% compared with the third quarter of 2022. On an operational1 basis, revenue for the third quarter of 2023 increased 8% compared with the third quarter of 2022, excluding the impact of foreign currency. Net income for the third quarter of 2023 was $596 million, or $1.29 per diluted share, an increase of 13% and 14%, respectively, on a reported basis.
Adjusted net income2 for the third quarter of 2023 was $629 million, or $1.36 per diluted share, an increase of 11% and 12%, respectively, on a reported basis, and an increase of 13% and 15%, respectively, on an operational basis. Adjusted net income for the third quarter of 2023 excludes the net impact of $33 million for purchase accounting adjustments, acquisition-related costs and certain significant items.
“Today we reported strong third quarter results of 8% operational growth in revenue and 13% operational growth in adjusted net income, based on our diverse portfolio across markets and species,” said Kristin Peck, Chief Executive Officer of Zoetis. “We showed balanced segment growth again this quarter, with 8% revenue growth in the U.S. and 8% operational revenue growth internationally. Our companion animal portfolio grew 11% operationally, driven by our major franchises in dermatology, pet parasiticides, osteoarthritis pain and diagnostics. Our livestock portfolio grew 3% operationally, driven by sales of poultry and cattle products.”
“We are on track to achieve our full-year operational guidance and have narrowed it around the mid-point of the range. We remain confident in the sustainable, underlying demand for animal health, as customers continue to place a premium on the animal health benefits our products deliver. We are executing well on drivers where we have more control, like the successful launch of Librela® in the U.S., while also mitigating the downside of macroeconomic declines in China. Once again, our diverse portfolio across product categories and geographies provides us with durable, reliable, long-term growth.”
Zoetis organizes and manages its commercial operations across two segments: United States (U.S.) and International. Within these segments, the company delivers a diverse portfolio of products for companion animals and livestock, tailored to local trends and customer needs. In the third quarter of 2023:
- Revenue in the U.S. segment was $1.174 billion, an increase of 8% compared with the third quarter of 2022. Sales of companion animal products increased 11%, driven by the company’s key dermatology portfolio, including Apoquel® and Cytopoint®, as well as the company’s parasiticide product Simparica Trio®. Also contributing to growth in the quarter was Solensia®, a monoclonal antibody for osteoarthritis pain in cats, and the company’s diagnostics portfolio of Vetscan® products. Sales of livestock products declined 2% in the quarter. Sales of cattle products decreased primarily due to a difficult comparable period versus the same quarter last year. Sales of swine products declined in the quarter, as a result of lower disease prevalence and unfavorable market conditions. Declines in cattle and swine were partially offset by growth in the poultry portfolio due to vaccines and the expanded use of Zoamix®, an alternative to antibiotic medicated feed additives (MFAs).
- Revenue in the International segment was $956 million, reflecting an increase of 8% on both a reported and operational basis, compared with the third quarter of 2022. Sales of companion animal products grew 12% on both a reported and operational basis, despite declines in China. Growth in the quarter was driven by the company’s monoclonal antibody products for osteoarthritis pain, Librela for dogs and Solensia for cats, as well as its key dermatology products, Apoquel and Cytopoint. Also contributing to growth in the quarter were Simparica® and Simparica Trio. Sales of livestock products grew 3% on a reported basis and 5% operationally. Growth in cattle was driven largely by price, improved supply and channel dynamics as well as strong market conditions in Brazil. Sales of poultry products experienced price increases across the international segment and MFAs grew in key regions. Sales in swine grew primarily from demand generation efforts in key and emerging markets.
INVESTMENTS IN GROWTH
Zoetis continues to grow key product franchises through additional claim extensions in major markets. In the third quarter, Simparica Trio (sarolaner/moxidectin/pyrantel), the company’s triple combination oral parasiticide for dogs, received approval in Australia and Canada for claims related to efficacy against sarcoptic and demodectic manges. Simparica Trio also received approval for two additional claims in Australia – Otodectes cynotis and flea tapeworms. Additionally, Simparica (sarolaner) received approval in Canada for claims related to Otodectes cynotis mange.
Zoetis also continues to advance pain management and dermatology innovation for companion animals across the globe. With the October launch of Librela (bedinvetmab injection) and Apoquel Chewable (oclacitinib chewable tablet) in the U.S., three of the company’s major franchises – including Solensia (frunevetmab injection) – are now available in most major markets around the world, with ongoing geographic expansion continuing in additional markets.
Zoetis is updating its full year reported 2023 guidance due to foreign exchange rates.
- Updates revenue to between $8.475 billion to $8.550 billion (narrows operational growth to a range of 6.5% to 7.5%)
- Updates reported net income to between $2.380 billion to $2.415 billion
- Updates adjusted net income to between $2.490 billion to $2.515 billion (narrows operational growth to a range of 7.5% to 8.5%)
- Updates reported diluted EPS of $5.14 to $5.21 due to the impact of foreign exchange rates
- Updates adjusted diluted EPS between $5.38 to $5.43 due to the impact of foreign exchange rates
This guidance reflects foreign exchange rates as of late October. Additional details on guidance are included in the financial tables and will be discussed on the company’s conference call this morning.
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide — from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.1 billion in 2022 with approximately 13,800 employees. For more information, visit www.zoetis.com.